GlassScriptPhysician profile
Michael A Schiano
NPI 1639171838
$4,288.75
in general payments reported to CMS, 2019-2025
25 companies · $522 in 2025
The $522 reported for 2025 was more than what a typical Gynecologic Oncology provider received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $346 · 2020: $372 · 2021: $975 · 2022: $740 · 2023: $635 · 2024: $699 · 2025: $522.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,856.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,855.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $838.43 | 2021-2025 | Keytruda, Lynparza |
| Glaxosmithkline, LLC. | $719.68 | 2020-2025 | Zejula |
| Astrazeneca Pharmaceuticals LP | $625.08 | 2019-2024 | Lynparza |
| Eisai INC. | $286.10 | 2019-2024 | |
| Ethicon US, LLC | $226.48 | 2021 | |
| Intuitive Surgical, INC. | $193.06 | 2021-2022 | |
| Abbvie INC. | $186.83 | 2021-2025 | |
| Seagen INC. | $173.21 | 2022-2023 | Tivdak |
| Tesaro, INC. | $117.06 | 2019 | |
| Myovant Sciences INC. | $111.71 | 2021 | |
| Dilon Technologies, INC. | $100.31 | 2024 | Hemoblast Bellows |
| Lupin INC. | $91.55 | 2019 | |
| Astellas Pharma US INC | $77.71 | 2024 | Veozah |
| Conmed Corporation | $73.01 | 2022-2023 | Airseal |
| Foundation Medicine, INC. | $71.09 | 2023 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Immunogen, INC. | $70.99 | 2023 | Elahere |
| Sumitomo Pharma America, INC. | $60.56 | 2024-2025 | Myfembree |
| Pfizer INC. | $54.73 | 2024-2025 | |
| Myriad Genetic Laboratories, INC. | $54.08 | 2023-2024 | Mychoice Cdx |
| Neurocrine Biosciences, INC. | $43.17 | 2022 | |
| Novartis Pharmaceuticals Corporation | $37.12 | 2021-2022 | |
| Caris Mpi, INC. | $23.96 | 2025 | Mi Cancer Seek |
| Hologic Sales and Service, LLC | $20.99 | 2021 | |
| Baxter Healthcare | $17.25 | 2024 | Perclot |
| Clovis Oncology, INC. | $14.59 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Schiano listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.